Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Blood ; 92(8): 2893-8, 1998 Oct 15.
Article in English | MEDLINE | ID: mdl-9763575

ABSTRACT

We have examined the cytotoxic effects of cyclic adenosine-3', 5'-monophosphate (cAMP) derivatives on multiple myeloma cells lines and determined that the 8-Chloro substituted derivative (8Cl-cAMP) is one of the most potent. We report here that 8Cl-cAMP is cytotoxic to both steroid sensitive and insensitive myeloma cells with a half maximal concentration of approximately 3 micromol/L. 8Cl-cAMP toxicity in myeloma cells is dependent on phosphodiesterase activity in the serum of cell culture medium. A metabolite of 8Cl-cAMP, 8-Chloro-adenosine (8Cl-AD), kills myeloma cells as effectively as 8Cl-cAMP. Adenosine deaminase (ADA) converts 8Cl-AD into 8Cl-inosine and abrogates the cytotoxic effects of 8Cl-cAMP, 8Cl-AMP, and 8Cl-AD, as does 5-(p-Nitrobenzyl)-6-Thio-Inosine (NBTI), an inhibitor of nucleoside uptake. These data suggest that 8Cl-cAMP must be converted to 8Cl-AD and that 8Cl-AD is the compound that enters the cell. Contrary to glucocorticoid-mediated cell death in myeloma cells, the pathway of 8Cl-AD-mediated cell death appears to be independent of interleukin-6 (IL-6) actions. Although the exact mode of action for this agent is currently unknown, its ability to kill steroid sensitive and insensitive multiple myeloma cells in an IL-6 independent fashion may offer exciting new therapeutic options.


Subject(s)
2-Chloroadenosine/analogs & derivatives , 8-Bromo Cyclic Adenosine Monophosphate/analogs & derivatives , Antimetabolites, Antineoplastic/pharmacology , Multiple Myeloma/pathology , Prodrugs/pharmacology , 1-Methyl-3-isobutylxanthine/pharmacology , 2-Chloroadenosine/toxicity , 8-Bromo Cyclic Adenosine Monophosphate/metabolism , 8-Bromo Cyclic Adenosine Monophosphate/pharmacology , Adenosine Deaminase/metabolism , Animals , Antimetabolites, Antineoplastic/metabolism , Apoptosis/drug effects , Biological Transport , Biotransformation , Cattle , Culture Media , Drug Resistance, Neoplasm , Drug Screening Assays, Antitumor , Humans , Interleukin-6/pharmacology , Phosphoric Diester Hydrolases/blood , Prodrugs/metabolism , Thioinosine/analogs & derivatives , Thioinosine/pharmacology , Tumor Cells, Cultured
2.
Clin Cancer Res ; 3(10): 1781-7, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9815564

ABSTRACT

Multiple myeloma is a neoplastic proliferation of plasma cells. Glucocorticoids are among the most effective agents against multiple myeloma, acting through the glucocorticoid receptor to induce programmed cell death. However, some patients do not respond to glucocorticoids, and those that do respond eventually develop resistance to this therapy. Alternative strategies using drugs that mediate cytotoxicity through complementary pathways have theoretical appeal. Cyclic adenosine-3',5'-monophosphate (cAMP) derivatives are cytotoxic to a number of cell lines of lymphocytic origin. cAMP analogues activate protein kinase A, affecting cell growth and differentiation. The cascade of events initiated by cAMP derivatives and glucocorticoid, although distinct, may share some distal molecular targets. We have found that pharmacological concentrations of 8-chloro-cAMP, dibutyryl-cAMP, and 8-bromo-cAMP are cytotoxic to multiple myeloma cells, enhance glucocorticoid effects, and can kill glucocorticoid-resistant clones. cAMP analogues induce apoptosis as demonstrated by the fragmentation of myeloma DNA chromatin in a distinctive ladder pattern. In contrast to glucocorticoids, cAMP growth inhibition cannot be reversed by exogenous interleukin 6. cAMP derivatives have activity against multiple myeloma and are appropriate candidates for clinical trials.


Subject(s)
Cyclic AMP/pharmacology , Drug Resistance, Neoplasm , Glucocorticoids/pharmacology , Multiple Myeloma/drug therapy , 8-Bromo Cyclic Adenosine Monophosphate/analogs & derivatives , 8-Bromo Cyclic Adenosine Monophosphate/pharmacology , Bucladesine/pharmacology , Butyrates/pharmacology , Colforsin/pharmacology , Cyclic AMP-Dependent Protein Kinases/metabolism , Dexamethasone/pharmacology , Enzyme Activation/drug effects , Humans , Interleukin-6/pharmacology , Multiple Myeloma/pathology , Tumor Cells, Cultured , Tumor Stem Cell Assay
SELECTION OF CITATIONS
SEARCH DETAIL
...